{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:11:46Z","timestamp":1794085906535,"version":"4.8.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032490","name":"Freedom Together Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032490","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.neurot.2025.e00712","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:31:19Z","timestamp":1753817479000},"page":"e00712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics"],"prefix":"10.1016","volume":"22","author":[{"given":"Akash","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valina L.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00712_bib1","article-title":"Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: ryan Costello declares no relevant financial relationships with ineligible companies","author":"Collins","year":"2025"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2025.e00712_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00712_bib4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) penetrant: a narrative review","volume":"14","author":"West","year":"2025","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00712_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease","volume":"28","author":"Nowell","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00712_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.71065","article-title":"Incretin-based therapies in Alzheimer's and Parkinson's Disease: advancing neuroprotection with dual and triple agonists-a review","volume":"8","author":"Mohammed","year":"2025","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00712_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment","volume":"179","author":"Trapp","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00712_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuroscience.2011.02.023","article-title":"Preproglucagon neurons project widely to autonomic control areas in the mouse brain","volume":"180","author":"Llewellyn-Smith","year":"2011","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/en.2014-1675","article-title":"Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain","volume":"156","author":"Heppner","year":"2015","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00712_bib14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00712_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J Comp Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.neuron.2017.09.042","article-title":"Enhanced AMPA receptor trafficking mediates the anorexigenic effect of endogenous glucagon-like peptide-1 in the paraventricular hypothalamus","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00712_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/nu12113304","article-title":"Glucagon-Like Peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress","volume":"12","author":"Diz-Chaves","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.neurot.2025.e00712_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2022.833449","article-title":"AMPA receptor function in hypothalamic synapses","volume":"14","author":"Royo","year":"2022","journal-title":"Front Synaptic Neurosci"},{"key":"10.1016\/j.neurot.2025.e00712_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.793004","article-title":"GLP-1 suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions","volume":"14","author":"Chen","year":"2021","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bph.15535","article-title":"The diverse effects of brain glucagon-like peptide 1 receptors on ingestive behaviour","volume":"179","author":"Williams","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00712_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1227\/NEU.0000000000000577","article-title":"Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury","volume":"76","author":"Chohan","year":"2015","journal-title":"Neurosurgery"},{"key":"10.1016\/j.neurot.2025.e00712_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2025.e00712_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/B978-0-12-381517-0.00013-8","article-title":"The role of GLP-1 in neuronal activity and neurodegeneration","volume":"84","author":"H\u00f6lscher","year":"2010","journal-title":"Vitam Horm"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3233\/JAD-143090","article-title":"The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease","volume":"46","author":"Hansen","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib27","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","volume":"221","author":"H\u00f6lscher","year":"2014","journal-title":"J Endocrinol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease","volume":"19","author":"Li","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00712_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36210-9","article-title":"Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction","volume":"8","author":"Kamei","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00712_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1205207","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies","volume":"14","author":"Kong","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00712_bib33","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"issue":"10103","key":"10.1016\/j.neurot.2025.e00712_bib34","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00712_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson's disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00712_bib36","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00712_bib37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1474-4422(24)00097-8","article-title":"Negative findings from trials with NLY01 or deferiprone for Parkinson's disease","volume":"23","author":"M\u00fcller","year":"2024","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00712_bib39","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s13311-021-01088-5","article-title":"Therapeutic potential of a novel glucagon-like peptide-1 receptor agonist, NLY01, in experimental autoimmune encephalomyelitis","volume":"18","author":"Gharagozloo","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib40","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s13311-023-01390-4","article-title":"The effects of NLY01, a novel glucagon-like peptide-1 receptor agonist, on cuprizone-induced demyelination and remyelination: challenges and future perspectives","volume":"20","author":"Gharagozloo","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00712_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106229","article-title":"Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort","volume":"93","author":"Balshi","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00712_bib42","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10787-022-00956-6","article-title":"Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK\/SIRT1 signaling and NLRP3 inflammasome","volume":"30","author":"Ammar","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00712_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032008","article-title":"Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00712_bib44","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.3390\/ijms25105059","article-title":"Exploring the role of metabolic hormones in amyotrophic lateral sclerosis","volume":"25","author":"Mo\u021b\u0103\u021b\u0103ianu","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96418-0","article-title":"The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1(G93A) and TDP-43(Q331K) transgenic mouse models of ALS","volume":"11","author":"Keerie","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00712_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134221","article-title":"Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia","volume":"5","author":"Igoillo-Esteve","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00712_bib47","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-021-01180-z","article-title":"Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease","volume":"9","author":"Park","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00712_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094972","article-title":"A systematic review of semaglutide's influence on cognitive function in preclinical animal models and cell-line studies","volume":"25","author":"Tipa","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00712_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.neurot.2025.e00712_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurot.2025.e00712_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","article-title":"Multifunctional nanoparticle-mediated combining therapy for human diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00712_bib54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11011-025-01649-z","article-title":"Tirzepatide: a novel therapeutic approach for Alzheimer's disease","volume":"40","author":"Alshehri","year":"2025","journal-title":"Metab Brain Dis"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00712_bib55","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/acschemneuro.4c00729","article-title":"Dual GLP-1 and GIP agonist tirzepatide exerted neuroprotective action in a Parkinson's disease rat model","volume":"16","author":"Delvadia","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"10479","key":"10.1016\/j.neurot.2025.e00712_bib56","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00712_bib57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00712_bib58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00712_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00712_bib60","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists for prevention of stroke among patients with and without diabetes: a meta-analysis with the SELECT and FLOW trails","volume":"57","author":"Gera","year":"2025","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-025-01423-9","article-title":"Emerging treatments for obesity: the role of GLP1 receptor agonists on stroke","volume":"25","author":"Mariscal","year":"2025","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.neurot.2025.e00712_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.950623","article-title":"Glucagon-like peptide-1 receptor agonists as potential myelination-inducible and anti-demyelinating remedies","volume":"10","author":"Sango","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00712_bib63","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nature Mental Health"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2025.e00712_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0025-7753(14)70107-1","article-title":"[Safety and tolerability of GLP-1 receptor agonists]","volume":"143","author":"Soldevila","year":"2014","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.neurot.2025.e00712_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1210347","article-title":"Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities","volume":"10","author":"Xie","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/2168479013513889","article-title":"Adaptive clinical trials: overview of early-phase designs and challenges","volume":"48","author":"Marchenko","year":"2014","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00712_bib67","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1871527322666230303114425","article-title":"APOE4 is a risk factor and potential therapeutic target for Alzheimer's disease","volume":"23","author":"Ayyubova","year":"2024","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00712_bib68","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","article-title":"Apolipoprotein E as a therapeutic target in Alzheimer's Disease: a review of basic research and clinical evidence","volume":"30","author":"Yamazaki","year":"2016","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00712_bib69","article-title":"The therapeutic potential of glucagon-like peptide 1 receptor agonists in traumatic brain injury","volume":"17","author":"Harej","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00712_bib70","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms","volume":"21","author":"Verges","year":"2022","journal-title":"Cardiovasc Diabetol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:10:20Z","timestamp":1762560620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925001904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1878747925001904"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00712","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00712"}}